The effect of early radiofrequency turbinate reduction, intranasal steroid, and antihistamine H-1 on persistent allergic rhinitis: a randomized clinical trial

Abstract Objective: We aimed to evaluate the effect of radiofrequency turbinate reduction as an initial treatment on clinical improvement, inflammatory mediators, and remodeling process. Methods: Between July 2018- February 2020, 32 patients with moderate-severe persistent AR were randomly divided into 2 groups. Intervention group received radiofrequency turbinate reduction followed by intranasal steroid and Antihistamine H-1 (AH-1), control group received intranasal steroid and AH-1. Both groups were evaluated for clinical improvement (using visual analogue scale based on total nasal symptoms score, peak nasal inspiratory flow, and turbinate size using imageJ) after 4 and 8 weeks of treatment. Inflammatory mediators (ELISA from nasal secretions was performed to measure ECP, IL-5, and HSP-70) and remodeling markers (nasal biopsy followed by immunohistochemistry examination was performed to evaluate MMP-9, TIMP-1, and PAI-1) were evaluated in week 4. Results: Three patients dropped out of the study, resulting in 16 patients in intervention group and 13 patients in control group. At week 4, clinical response improved significantly in the intervention group compared to control group (Chi-Square test, p<0.05). Compared to control, intervention group experienced a reduction of IL-5 and no significant change in ECP level (Mann Whitney test, p>0.05). Reduction in the ratio of MMP-9/TIMP-1 were significantly higher in intervention group (unpaired t-test, p< 0,05). Meanwhile, increase in HSP-70 in the intervention group was slightly lower than in control group, but the difference with control group was not significant (Mann Whitney test, p>0.05). Conclusion: Early radiofrequency turbinate reduction followed by pharmacotherapy given to persistent moderate-severe AR patients give more improvement only in early clinical symptoms and reduce MMP-9/TIMP-1 ratio, thus it might be suggested as one of the adjuvant therapies for the management of moderate-severe persistent AR. However, further investigation with a larger sample size and longer follow-up period is needed. Level of evidence: 1B.

Efficacy of Levocetirizine, Prednisolone and their combination in the treatment of chronic urticaria: a comparative study

Background: Urticaria results from many different stimuli and numerous factors like immunologic, non-immunologic, genetic and modulating factors which are involved in its pathogenesis and ultimately converge on mast cells and basophils to release mediators and produce urticarial lesions. This study is aimed to compare the therapeutic effectiveness of Levocetirizine (newer generation H1 blocker), prednisolone (glucocorticoid) and their combination in the treatment of chronic urticaria.Methods: Group I (34 patients received tab Levocetirizine alone 5mg daily for 15 days). Group II (33 patients received tab Prednisolone alone 20mg /day for initial 3 days and later dose was gradually tapered by 5mg /day every 3 days to 5mg/day with total duration of 12 days). Group III (33 patients received the combination of Levocetirizine and Prednisolone).Results: The Group -I patients average eosinophil count before and after treatment was 4±1.4 and 2.4±0.8 respectively, with an average difference of 1.7±1.3. In Group - II patients average eosinophil count before and after treatment was 4.0±1.1 and 2.5±0.3 respectively, with an average difference of 1.5±1.1. In the Group - III patients the average eosinophil count before and after treatment was 4.3±1.0 and 2.1±1.0 with an average difference of 2.2±1.3. In G-I (n=34).Conclusions: Statistical analysis of the present study showed that the combination of Levocetirizine and prednisolone therapy was significantly (P<0.05) greater than prednisolone alone therapy and improvement with Levocetirizine alone (79%) was almost similar to combination therapy (85%).

Updated treatment guideline of chronic spontaneous urticaria

Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, is a common chronic inflammatory skin disorder that has a prevalence of 0.5% to 1% in the general population. It affects daily normal life and work productivity, with significant impacts on quality of life. Generally, the management of CSU uses a step-wise approach. Although second-generation H1 antihistamines are an effective mainstay of CSU, approximately 20% of patients are resistant to conventional antihistamine monotherapy. Evidence-based and expert consensus-based treatment guidelines of CSU can be a useful resource for primary care physicians and specialists. This review presents diverse information to support decision-making for individualized treatment plans in this special population. Several major therapeutic advances have occurred in recent years. Omalizumab, an immunoglobulin G humanized monoclonal anti-immunoglobulin E antibody that prevents binding of immunoglobulin E to the high-affinity immunoglobulin E receptor has shown safety and efficacy in patients with intractable CSU. In well-controlled clinical trials in patients with refractory CSU who received add-on therapy with subcutaneous omalizumab (300 mg every 4 weeks for 12 or 24 weeks), the rates of complete response were significantly higher in the omalizumab group (relative risk, 4.55; P < 0.0001). The introduction of omalizumab as an add-on therapy to H1 antihistamines as a management option has markedly improved the therapeutic possibilities for CSU and the quality of life of CSU patients. Nevertheless, many patients still do not tolerate or benefit from existing therapies, including omalizumab. There are ongoing studies investigating the treatment potential of novel therapeutic targets in CSU.

Impact of Jumihaidokuto (Shi-Wei-Bai-Du-Tang) on Treatment of Chronic Spontaneous Urticaria: A Randomized Controlled Study / 中国结合医学杂志

OBJECTIVE@#To study the effect of Jumihaidokuto (Shi-Wei-Bai-Du-Tang, ) in the management of chronic spontaneous urticaria.@*METHODS@#A randomized two-arm, parallel group study was conducted to compare the effect of Jumihaidokuto (6 g daily) with a control for 8 weeks. Concomitant therapy (e.g., antihistamines) was continued. Twenty-one subjects with severe chronic urticaria were enrolled in this study. The primary treatment outcome was the severity score proposed by the Japanese Dermatological Association. Secondary outcomes were quality of life (Skindex-16), itch intensity (Visual Analogue Scale), and patients' subjective disability due to wheal or itch. After the subjects were randomly assigned to groups by block randomization, 10 received Jumihaidokuto, and 11 did not. All subjects had already taken antihistamines.@*RESULTS@#Improvement was significant when comparing the severity score of the Jumihaidokuto group with that of the control group (P<0.01). Skindex-16 values for both groups gradually decreased in the same fashion.@*CONCLUSION@#Concomitant use of Jumihaidokuto with antihistamine was more effective than antihistamine alone in the management of chronic idiopathic urticaria. (Trial Registration No. UMIN000007251).

Urticária crônica espontânea refratária aos anti-histamínicos: opção por ciclosporina / Antihistamine-refractory chronic spontaneous urticaria: opting for cyclosporine

Introdução: Anti-histamínico de segunda geração (AH1 2ªG) é o tratamento de escolha para pacientes com urticária crônica espontânea (UCE). Porém, cerca de 50% dos pacientes não responde a este tratamento. A ciclosporina é uma opção para os quadros mais graves. A ciclosporina tem propriedades imunossupressoras potentes, mas, apesar de sua eficácia, seu uso é limitado devido a diversos efeitos colaterais importantes. Objetivo: O objetivo deste estudo foi avaliar a resposta à ciclosporina em pacientes com UCE refratária aos anti-histamínicos. Método: Estudo retrospectivo baseado no prontuário eletrônico de pacientes com UCE refratária aos AH1 2ªG e que não responderam à introdução de outros medicamentos para controle da urticária. A ciclosporina foi indicada para todos os pacientes. A dosagem de D-dímero foi realizada em alguns pacientes. Resultados: Trinta pacientes participaram do estudo. Desses pacientes, 80% eram do sexo feminino, e a média de idade era de 42,8 anos. Previamente à introdução da ciclosporina, todos estavam em uso de AH1, 60% de AH2, 67% de montelucaste, 33,3% de hidroxicloroquina, e 56,7% de corticoide oral. A mediana de tempo de uso da ciclosporina foi de 11,5 meses. Em relação à eficácia, 40% dos pacientes apresentaram melhora dos sintomas, 40% não responderam ao tratamento, e em 20% dos pacientes a resposta não foi avaliada por suspensão da ciclosporina devido a efeitos colaterais, ou não foi introduzida devido a alterações clínicas ou laboratoriais prévias. Houve aumento dos níveis pressóricos em 9 pacientes (30%), e nefrotoxicidade em 5 pacientes (16,7%). Conclusões: Embora a ciclosporina seja uma boa opção terapêutica para pacientes com UCE refratária aos AH1, os efeitos colaterais são frequentes e devem ser monitorados.

Introduction: Second-generation antihistamines (sgAH1) are the treatment of choice for patients with chronic spontaneous urticaria (CSU). However, about 50% of the patients do not respond to this treatment. Cyclosporine is an option for more severe presentations. This drug has potent immunosuppressive properties. Despite its effectiveness, use is limited due to several serious side effects. Objective: The aim of this study was to assess response to cyclosporine in patients with antihistamine-refractory CSU. Method: This retrospective study was based on the electronic records of patients with sgAH1-refractory CSU who did not respond to the introduction of other drugs to control urticaria. Cyclosporine was indicated for all patients. D-dimer dosage was performed in some patients. Results: Thirty patients participated in the study. Of these, 80% were female and the mean age was 42.8 years. Prior to the introduction of cyclosporine, all patients were using AH1, 60% AH2, 67% montelukast, 33.3% hydroxychloroquine, and 56.7% oral corticosteroids. Median time of cyclosporine use was 11.5 months. Regarding efficacy, 40% of the patients showed improvement of symptoms, 40% did not respond to treatment, and in 20% response was not evaluated because the medication was withdrawn due to side effects or was not introduced based on previous clinical or laboratory abnormalities. There was an increase in blood pressure levels in 9 patients (30%) and nephrotoxicity in 5 (16.7%). Conclusions: Even though cyclosporine is a good therapeutic option for patients with AH1-refractory CSU, side effects are frequent and should be monitored.

Treatment optimization for dermatitis medicamentosa in a patient with abnormal liver function associated with infection / 药学实践杂志

Objective To optimize the treatment plan for dermatitis medicamentosa in a patient with abnormal liver function associated with infection.Methods The culprit medication for drug eruption was identified by reviewing the patient′s liver and kidney function, routine blood count, therapeutic drugs, allergic history, by analyzing the characteristics of the compounding medication, combined with literature search on drug eruption diagnosis and treatments.Following the antihistamines and glucocorticoid use guidelines, the treatment plan was optimized by selecting appropriate antihistamines and glucocorticoids based on their metabolism and excretion pathway.Results The rash was poorly controlled after clinical pharmacist′s initial recommendation to use chlorpheniramine (intramuscular injection) and cetirizine (oral).The clinical pharmacist further suggested dexamethasone intravenous drip.The patient recovered well with the combination therapy of antihistamines and glucocorticoid.Conclusion When drug eruption occurred, clinical pharmacists should evaluate patient′s disease and medications comprehensively, provide timely and accurate pharmaceutical care to patients.

Prescription practice of antihistamines for acute upper respiratory tract infections in pediatric patients in a local emergency department in Hong Kong / 世界急诊医学杂志（英文）

@#BACKGROUND: Currently there is very limited data in the literature assessing the prevalence of antihistamine prescription, and there is no local prevalence data about the prescription of antihistamine agents among primary practitioner and emergency physicians. The objectives are 1) to report the prevalence of antihistamine prescription for children less than 6 years old with acute upper respiratory infection and 2) to explore the associated factors for the prescription practice. METHODS: This is a cross-sectional study. All consecutive cases of paediatric patients aged 6 or below who presented to the emergency department during a study period of one week from April 1 to July 4, 2009 with diagnosis of acute upper respiratory infection were included. Totally 162 patients were included. RESULTS: Among the 162 cases, 141 (87%) patients were prescribed one antihistamine of any group. Sixty (37%) patients were prescribed two or more antihistamines. In multivariate logistic regression model, age was found to be significantly (P<0.001) associated with multiple antihistamine prescription (OR=1.042, 95%CI=1.02 to 1.06). Years of graduation of attending physician for more than 5 years was also a strong predictor of multiple antihistamine prescription (OR=4.654, 95%CI=2.20 to 9.84, P<0.001). CONCLUSION: In the local emergency department, patients' age and the years of graduation from medical school of the attending physician were predictors of multiple antihistamine prescription for acute upper respiratory infections for children aged less than 6.

A Case Involving Chronic Diarrhea over an Extended Period of Time following Anticancer Treatment in a Patient with Edema and Which Was Improved by Olopatadine Administered for Another Purpose

<p>Introduction: We are reporting on our experience with a case involving chronic diarrhea that had been continuing for 14 years following anticancer treatment, in which diarrhea and the nutritional status of the patient were unintentionally improved by administered antihistamine. Subject: A 48-year-old female. Fourteen years ago, surgery, chemotherapy, and total pelvic radiotherapy were carried out for cervical cancer, immediately after which diarrhea continued. A laparotomy was performed 11 years ago for Ileus, and radiation enterocolitis was diagnosed upon pathological examination 8 years ago. One month ago, she experienced swelling of the lower limbs after acute cellulitis and visited our outpatient palliative care. Leaking edema due to low nutrition remained following the remission of lymphedema. Ten days prior to re-examination, a maximum dosage of 20 mg/day of olopatadine was prescribed by another department against urticaria, and at the same time, remission of her diarrhea was observed. Oral administration of folic acid and vitamin was completed by continuing small doses, leading to a rise in CK and disappearance of the edema. Discussion: It may be believed that chronic diarrhea was relieved by olopatadine administered for another purpose due to the inhibitory action of 5-hydroxytryptamine 2A receptor, which is a subfamily of serotinin having histamine 1 inhibitory action and the action to increase the bowel movements.</p>

In vitro antihistamine-releasing activity of a peptide derived from wasp venom of Vespa orientalis

Objective: To investigate the antihistamine-releasing effect of a peptide isolated from wasp venom of Vespa orientalis. Methods: This peptide was separated from crude venom by chromatography methods and mass spectrometry. Then various concentrations (2, 4, 8, 16, 32, 64, 128 and 256 μmol/L) of the peptide were incubated with mast cells and lactate dehydrogenase assay was performed. Results: No significant effect was observed in lactate dehydrogenase absorbance under 128 μmol/L concentration. This implied that the peptide did not cause cell death in mast cells and consequently, histamine release did not happen. Moreover, the results showed the IC

Safety and efficacy of dimenhydrinate for treatment of motion sickness / 第二军医大学学报

Dimenhydinate, an antihistamine agent, is effective for treating motion sickness and has a value for both civil and military application. We searched PubMed, the Cochrane Ear, Nose and Throat Disorders Group Trials Register, the Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, Web of Science, BIOSIS Preview for related literatures. In this paper we reviewed the retrieved literatures and discussed the safety and efficacy of dimenhydrinate in the treatment of motion sickness. It was showed that although the first choice for motion sickness was scopolamine, dimenhydrinate was, however, the first choice for nausea and vomiting, which is partly because it can reduce gastric motility during motion sickness-inducing stimuli. Therefore, dimenhydrinate might be the first choice for treating motion sickness combined with vomiting and nausea.

Effectiveness of intranasal corticosteroid plus antihistamine on allergic rhinitis：a systematic review / 军事医学

Objective To systematically review the efficacy of corticosteroid nasal spray plus antihistamine versus either therapy given alone or placebo in patients with allergic rhinitis (AR).Methods The PubMed, EMbase, Google Scholar and The Cochrane Library were electronically searched for randomized controlled trials ( RCTs ) about the efficacy of corticosteroid plus antihistamine for AR .The duration of the search was from the inception of the databases to April 2015 . After literature selection , data extraction and quality assessment conducted by two reviewers independently , meta-analysis was conducted using RevMan 5.3 software.Results Ten studies involving 6568 patients were finally included .The qualitative analysis showed that the combination therapy had greater efficacy than oral antihistamines alone or placebo on improving symptoms.The results of meta-analysis showed that pooled results of two trials failed to show significant difference in total nasal symptoms between combination therapy and intranasal corticosteroid alone [ WMD =-0.20, 95%CI (-0.38,-0.01),P=0.04].The cumulative meta-analysis of six RCTs showed that the combination therapy was superior to intranasal corticosteroid alone[WMD=-1.16, 95%CI( -1.49,-0.83), P<0.00001], intranasal antihistamine alone[WMD=-1.73, 95%CI( -2.08,-1.38),P<0.00001], and placebo [WMD =-2.81, 95%CI( -3.16,-2.47), P<0.00001].Conclusion Intranasal corticosteroid plus oral antihistamine has similar efficacy to intranasal corticosteroid alone, greater efficacy than oral antihistamines alone or placebo in reducing nasal symptoms for AR patients . Intranasal corticosteroid plus intranasal antihistamine is significantly superior to either therapy given alone or placebo .

Clinical Observation of Pregabalin Assisting Anti-histamine Drugs in the Treatment of Secondary Skin Pru-ritus in Uremic Patients Underwent Maintenance Hemodialysis / 中国药房

OBJECTIVE:To observe the clinical efficacy and safety of pregabalin assisting anti-histamine drugs in the treat-ment of secondary skin pruritus in uremic patients underwent maintenance hemodialysis. METHODS:140 uremic patients with sec-ondary skin pruritus underwent maintenance hemodialysis were randomly divided into control group and treatment group,with 70 cases in each group. Control group was given loratadine orally,10 mg,qd. Treatment group was additionally given pregabalin on the basis of control group,75 mg,po,at night of hemodialysis end,increasing by 75 mg every week if no obvious relief was found,maximal dose of 300 mg. Both group received 3 months of treatment. Clinical efficacy,VAG itching score,modified Duo score,PSQI score before and after treatment and the incidence of ADR were compared between 2 groups. RESULTS:Total effec-tive rate of treatment group (90.00%) was significantly higher than that of control group (71.43%),with statistical significance (P0.05). CONCLUSIONS:Pregabalin assisting anti-histamine drugs in the treatment of secondary skin pruritus in uremic patients with maintenance hemodialysis can efficiently relieve the itching symptoms,improve sleep quality,and not increase the risk of ADR.

Reversible dementia due to neurocysticercosis: improvement of the racemose type with antihistamines / Demência reversível por neurocisticercose: melhora da forma racemosa com o uso de anti-histamínicos

Infection of the human central nervous system (CNS) by the larvae of Taenia solium, termed neurocysticercosis (NCC), is endemic in most developing countries, where it is a major cause of acquired seizures and other neurological morbidity, including neuropsychiatric symptoms. However, despite its frequent manifestation, some findings, such as cognitive impairment and dementia, remain poorly understood. Less commonly, NCC may affect the ventricular system and subarachnoid spaces and this form is known as extraparenchymal neurocysticercosis. A particular presentation of the subarachnoid form is called racemose cysticercosis, which has a progressive pattern, frequently leads to hydrocephalus and can be life-threatening. Here we review a case of the racemose variety of cysticercosis, complicated by hydrocephalus and reversible dementia, with remission of symptoms after derivation and that remained stable with use of dexchlorpheniramine. We discuss the challenges in diagnosis, imaging findings, treatment and follow-up of this disease.

A infecção do sistema nervoso central (SNC) pela larva da Taenia solium, intitulada neurocisticercose (NCC) é endêmica na maior parte dos países "em desenvolvimento", onde é a principal causa de convulsão adquirida, além de outras morbidades neurológicas, entre elas, sintomas neuropsiquiátricos. No entanto, apesar de manifestações neuropsiquiátricas serem frequentes, alguns achados, tais como comprometimento cognitivo e demência, continuam a ser mal compreendidos. Menos frequentemente, NCC pode afetar o sistema ventricular e espaços subaracnóideos e esta forma é conhecida como NCC extraparenquimatosa. Uma apresentação particular subaracnóidea, chamada cisticercose racemosa, é encontrada mais raramente, evolui de forma progressiva, associada a hidrocefalia e pode levar a morte. Neste artigo revisamos um caso da variedade racemosa de NCC, complicada com hidrocefalia e demência reversível que evoluiu com remissão dos sintomas após derivação ventricular e permaneceu estável com uso de dexclorfeniramina. Discutimos os desafios no diagnóstico, achados de imagem, tratamento e acompanhamento desta forma de doença.

A randomized placebo-controlled double-blind pilot study of methotrexate in the treatment of H1 antihistamine-resistant chronic spontaneous urticaria.

Background: Chronic urticaria not responsive to antihistamines is a diffi cult disease to manage. Methotrexate has been used in diffi cult chronic urticarias with some benefi t. Objective: To evaluate the effi cacy of methotrexate in the treatment of chronic spontaneous urticaria poorly responsive to H1 antihistaminics. Methods: In a randomized double-blind trial at the Department of Dermatology and Venereology of a tertiary care centre, 29 patients with chronic spontaneous urticaria not responding well to H1 antihistaminics were recruited. Patients were randomly allocated to receive either a weekly dose of oral methotrexate 15 mg or placebo (calcium carbonate) for a total duration of 12 weeks, after which treatment was stopped and patients were followed up for relapse of urticaria. Each group also received levocetrizine 5 mg once daily for symptom control. Primary outcome measured was a reduction by >2/3rd of baseline urticaria scores after 12 week therapy. Secondary outcome was a reduction in antihistamine requirement after stopping therapy. Results: Fourteen patients were randomized to the methotrexate group and fi fteen patients to the placebo group. Out of 17 patients who completed therapy, the primary outcome was achieved by 3.5 ± 1.9 (out of 10) patients in the methotrexate group and by 3.67 ± 1.03 (out of 7) patients in the placebo group (P > 0.05). Ten patients followed up, after stopping therapy, for a mean period of 3.5 ± 2.4 months; 3 remained in remission and 7 had relapsed. One patient had uncontrollable nausea and vomiting after taking methotrexate and was withdrawn from the study. The placebo group did not experience any side effects. Conclusions: Methotrexate 15 mg weekly for 3 months did not provide any additional benefi t over H1 antihistamines in this study but an adequately powered study with longer follow up is required to assess its utility.

Screening of cetirizine for analgesic activity in mice.

Background: Pain is the most common symptom for which patients approach doctors. We have multitude of drugs for pain relief, but they have serious side effects ranging from peptic ulcer (e.g. NSAIDs) to renal failure. The other group, opioids have well known side effects ranging from sedation to drug dependence. So a search for a drug for analgesia with high therapeutic effect and fewer side effects will be a boon for the patients. The objective of this study was to find whether cetirizine, a second generation antihistaminic drug, has got any analgesic activity in mice. Methods: Ten adult albino mice weighing 20-30 grams of either sex were randomized to two groups (n=5). Group I: control group (Treated with solvent 0.1 ml/kg), Group II: Test group (Cetirizine 1mg/kg). All drugs were given orally. The analgesic activity was evaluated by using tail flick, tail immersion and tail clip methods. Reaction time of animals to pain sensation before and after Cetirizine administration were noted at 0, 15, 30, 60 and 90 minutes time intervals respectively on Day 1, 3, 5, 7, 10. Results: Mean reaction time was expressed as Mean±SEM, and one way ANOVA was used to assess statistical significance. Cetirizine was found to have statistically significant analgesic effect in mice and time dependent increase in analgesic effect were observed in all three pain models and maximum analgesic activity was observed at 60 minutes (p<0.001) after drug administration. Conclusions: Through this study, Cetirizine, a second generation antihistamine, is found to have significant analgesic activity in mice. This effect has to be studied further elaborately in animals as well as in humans.

A case of levocetirizine-induced fixed drug eruption and cross-reaction with piperazine derivatives

Fixed drug eruption is an uncommon adverse drug reaction caused by delayed cell-mediated hypersensitivity. Levocetirizine is an active (R)-enatiomer of cetirizine and there have been a few reports of fixed drug eruption related to these antihistamines. We experienced a case of levocetirizine-induced fixed drug eruption and cross-reaction with other piperazine derivatives confirmed by patch test. A 73-year-old female patient presented with recurrent generalized itching, cutaneous bullae formation, rash and multiple pigmentation at fixed sites after taking drugs for common cold. She took bepotastine besilate (Talion®) and levocetirizine (Xyzal®) as antihistamine. She took acetaminophen, pseudoephedrine 60 mg / triprolidine 2.5 mg (Actifed®), dihydrocodeinebitartrate 5 mg / di-methylephedrine hydrochloride 17.5 mg / chlorpheniramine maleate 1.5 mg / guaifenesin 50 mg (Codening®) and aluminium hydroxide 200 mg / magnesium carbonate 120 mg (Antad®) at the same time. Patch test was done with suspected drugs and the result was positive with levocetirizine. We additionally performed patch test for other antihistamines such as cetirizine, hydroxyzine, fexofenadine and loratadine. Piperazine derivatives (cetirizine and hydroxyzine) were positive, but piperidine derivatives (fexofenadine and loratadine) were negative to patch test. There was no adverse drug reaction when she was challenged with fexofenadine. We report a case of levocetirizine-induced fixed drug eruption confirmed by patch test. Cross-reactions were only observed in the piperazine derivatives and piperidine antihistamine was tolerant to the patient.

An overview and considerations in prescribing H1-antihistamine

H1-antihistamines have been prescribed widely for the treatment of allergic diseases, such as rhinitis, atopic dermatitis, and urticaria besides common colds since the 1940s. H1-antihistamines are classified by chemical structures (akylamine, piperazine, piperidine, ethanolamine, ethylendiamine, and phenothiazine) or functionally by permeability through blood brain barrier (first or second generation). The first generation antihistamines have been prescribed up to now with several adverse effects such as central nervous system dysfunction, anticholinergic and antiserotonic action and cardiotoxicity with overdose. Hence second generation antihistamines are recommended for the treatment of allergic rhinitis and urticaria. Physicians should consider concomitant diseases or medications when prescribing first generation antihistamines.

The Effects of Anti-histamine and Leukotriene Receptor Antagonist Against Ischemia-Reperfusion Injury

PURPOSE: The purpose of this study was to investigate the role of mast cells and their product, histamine and leukotriene in ischemia-reperfusion injury. METHODS: Forty Sprague-Dawley rats were divided into four groups. (Group I: Control group without ischemia, Group II: Normal saline with ischemia, Group III: Cimetidine with ischemia, Group IV: Zafirlukast with ischemia) Skin flap was elevated and ischemic insult was given by clamping the artery for 12 hours. Before reperfusion, the rats were treated with saline, cimetidine and zafirlukast. Flap survival was evaluated at 7 days. Neutrophil counts, mast cell counts were evaluated 24 hours after reperfusion. RESULTS: Flap survival rate in the control group was 92.33%, whereas normal saline group had 37.34% survivals. Cimetidine and zafirlukast treated group showed significantly higher survival rates than normal saline group. The neutrophil and mast cell counts in cimetidine and zafirlukast treated group were significantly decreased than normal saline group. Cimetidine treated group showed higher survival rate and lower cell counts than zafirlukast treated group. CONCLUSION: The administration of cimetidine and zafirlukast can decrease neutrophils and mast cells caused by ischemia-reperfusion and increase flap survivals. It is suggests that antihistamine and leukotriene receptor antagonist have protective effect against ischemia-reperfusion injury to skin flap in rat.

Nalbuphine vs. chlorpheniramine in reducing intrathecal opioid-induced pruritus in parturients undergoing lower-segment caesarean section

Background: Pruritus is a common complication of intrathecal opioids and numerous medications have been used to prevent or treat this complication. However, the efficacy of these medications vary. The choice of medications also depends on the availability and the cost. We performed a randomised double-blind study to evaluate whether nalbuphine is as effective as chlorpheniramine, a medication that is commonly used for treating pruritus for the treatment of intrathecal opioid-induced pruritus in parturients undergoing lower-segment caesarean section. Materials and Methods: Two hundred and thirty four parturients with American Society of Anaesthesiologists (ASA) physical status I or II who had intrathecal opioid-induced pruritus were assigned to receive either intravenous nalbuphine (4 mg eight-hourly) or intravenous chlorpheniramine (5 mg eight-hourly) for a period of 24 hours. Pruritus was assessed using a qualitative scale at pre-treatment, six, nine, 12 and 24 hours post-treatment. Results: The occurrence of intrathecal opioid-induced pruritus was significantly reduced in parturients treated with intravenous nalbuphine as compared to intravenous chlorpheniramine at all intervals studied. Conclusion: In conclusion, nalbuphine is more effective than chlorpheniramine in reducing intrathecal opioid-induced pruritus for parturients undergoing lower-segment caesarean section.

Treatment of Chronic Spontaneous Urticaria

Chronic spontaneous urticaria is defined as persistent symptoms of urticaria for 6 weeks or more. It is associated with autoimmunity in approximately 45 percent of patients. Therapy is often difficult however the initial approach should employ high-dose non-sedating antihistamines; 4-6 tablets/day may be necessary. It has been shown that the response to 4 tablets/day exceeds 3, and exceeds 2, which exceeds 1. However the dose that corresponds to the maximal dose of first generation antihistamines (hydroxyzine, diphenhydramine) used previously, is 6/day. Yet over half the patients are refractory to antihistamines and other agents should be tried next. Whereas current guidelines (published) often add leukotriene antagonists and/or H2 receptor antogonists next, these are of little utility. Likewise drugs effective for urticarial vasculitis (colchicine, dapsone, sulfasalazine, hydroxychloroquine) are effective in a small percentage of patients and no study suggests that the response rate of any of them exceeds the 30% placebo responses seen in most double-blind, placebo controlled studies. The drugs that are effective for antihistamine-resistant chronic spontaneous urticaria are corticosteroids, cyclosporine, and Omalizumab. Use of steroids is limited by toxicity. If used at all, a dose of no more than 10 mg/day should be employed with a weekly reduction of 1 mg. The response rates to cyclosporine and Omalizumab are each close to 75%. Cyclosporine can be used effectively if care is taken to monitor blood pressure, urine protein, blood urea nitrogen, and creatinine, every 6 weeks. Omalizumab has the best profile in terms of efficacy/toxicity and, once approved by federal agencies for use in chronic spontaneous urticaria, a dramatic change in the treatment paradigm, whether associated with autoimmunity or not, is predicted. A phase 3 trial is currently in place. Refractoriness to both Omalizumab and cyclosporine is expected to be less than 5 percent of patients. Other agents, can then be tried.